Given the establishment of TYK2 as a susceptibility gene in auto-inflammation, immunodeficiency and other immune responses as well as in cancer [39,87,88], the prospect of therapies targeting TYK2 in immunodeficiency and autoimmune diseases exists. This evidence concerns the gene TYK2 and Immunodeficiency.